- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03857022
A Study to Evaluate the Effects of EECP in Patients With Heart Failure
An Open-label Study to Evaluate the Effects of Enhanced External Counterpulsation on Tapering Inotropic Agents, Reduction of Brain Natriuretic Peptide and Rehospitalization in Patients With Heart Failure
Studieöversikt
Detaljerad beskrivning
Chronic heart failure (CHF) patients dependent on intravenous infusion of positive inotropic agents have not only high mortality rate but also high morbidity in the prolonged hospital course. Medications such as angiotensin conversion enzyme inhibitor or angiotensin II receptor blocker may improve the survival of CHF patients. However, their implication is limited by the presence of hypotension secondary to low cardiac output. External enhanced counterpulsation (EECP), which generates the arterial and intracoronary hemodynamics similar to those of the intra-aortic balloon pump, is a recently approved treatment modality for patients with angina and heart failure. It can improve exercise capacity, quality of life and functional status.
Forty patients of (1) impaired left ventricular systolic function (LVEF 40%) and are dependent on intravenous infusion of positive inotropic agents but (2) without significant aortic regurgitation, overt fluid overload, or symptomatic peripheral arterial insufficiency will be included. They will be randomly allocated into EECP or control groups (n=20 for each). The EECP therapy was given as a 1-hour session, once daily, for a total of 35 sessions. The daily urine amount, blood pressure, time for taper off positive inotropic agents, length of hospital stay, and will be monitored daily in the hospital stay. Patients will be followed-up if he or she can be released from hospital and the mortality, readmission for heart failure, and 6-minute walking distance will be checked at the end of 6th month. Plasma natriuretic peptide (BNP) levels will be checked at enrollment, day 35, and 6th month.
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Taipei, Taiwan, 10002
- Rekrytering
- National Taiwan University Hospital
-
Kontakt:
- Chii-Ming Lee
- Telefonnummer: 0972-651-087
- E-post: chiiminglee@ntu.edu.tw
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria All answers must be "Yes" for study entry.
- Male or female patients between 21-80 years of age.
- Patients who have documented evidence of HF.
Evidence of HF required at least one of the following:
LVEF <40%. As assessed with 3 months prior to enrollment, and LVEF can be measured through echocardiogram or radionuclide angiocardiography (RNA); Clinical symptoms of HF, namely the presence of 2 major criteria or 1 major criterion + 2 minor criteria according to the Framingham score; NYHA Fc III or IV ACC/AHA stage D 3. Treated with inotropic agents. Inotropic agents include dopamine, dobutamine, milrinone, norepinephrine. Low dose is included as well. 4. Patients who sign the informed consent . Exclusion criteria All answers must be "No" for study entry.
- Patients who had MI or coronary artery bypass grafting (CABG) within three months prior to the initiation of EECP treatment.
- Patients who had transcatheter intervention (PCI) within 2 weeks prior to the initiation of EECP treatment.
- Significant valvular heart disease, acute myocarditis.
- Uncontrolled hypertension (blood pressure 180/100 mmHg).
- Permanent pacemakers or implantable cardioverter defibrillators.
- Non bypassed left main coronary with a luminal stenosis greater than 50%.
- Severe symptomatic peripheral vascular disease.
- History of deep vein thrombosis.
- Phlebitis or stasis ulcer.
- Bleeding diathesis, warfarin use with International Normalized Ratio 2.0.
- Arial fibrillation or frequent ventricular premature beats that interferes with enhanced external counterpulsation triggering.
- Baseline ECG abnormalities that would interfere with interpretation of exercise ECG.
- Pregnant women, or women of childbearing potential but not using adequate birth control.
- Any medical, psychological, cognitive, social or legal condition that would interfere with the ability of patient to give an Informed Consent and/or his or her capacity to comply with all study requirements, including the necessary time commitment.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Enhanced External Counterpulsation
Subjects of Heart failure with 'Enhanced External Counterpulsation" therapy
|
The EECP therapy was given as a 1-hour session, once daily, for a total of 35 sessions.
The daily urine amount, blood pressure, time for taper off positive inotropic agents, length of hospital stay, and will be monitored daily in the hospital stay.
Patients will be followed-up if he or she can be released from hospital and the mortality, readmission for heart failure, and 6-minute walking distance will be checked at the end of 6th month.
Plasma natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels will be checked at enrollment, day 35, and 6th month.
Andra namn:
|
Inget ingripande: No 'Enhanced External Counterpulsation"
Subjects of Heart failure without 'Enhanced External Counterpulsation" therapy
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
the natriuretic peptide (NT-pro-BNP) level will be reduced.
Tidsram: 7 week
|
the natriuretic peptide (NT-pro-BNP) level will be reduced
|
7 week
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Weaning from intravenous infusion of positive inotropic agent
Tidsram: 24 week
|
Weaning from intravenous infusion of positive inotropic agent
|
24 week
|
Decrease the length of hospital stay.
Tidsram: 24 week
|
Decrease the length of hospital stay.
|
24 week
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Chii-Ming Lee, PhD, National Taiwan Unerversity Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 201805058DIPA
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hjärtsvikt
-
Region SkaneAnmälan via inbjudanHjärtsvikt New York Heart Association (NYHA) klass II | Hjärtsvikt New York Heart Association (NYHA) klass IIISverige
-
Taichung Veterans General HospitalRekryteringKontinuerlig Fetal Heart Beat Monitor och analys efter Spinal AnestesiTaiwan
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan... och andra samarbetspartnersHar inte rekryterat ännuHjärtsvikt, systolisk | Hjärtsvikt Med Minskad Ejection Fraktion | Hjärtsvikt New York Heart Association Klass IV | Hjärtsvikt New York Heart Association Klass IIIPolen
-
University of WashingtonAmerican Heart AssociationAvslutadHjärtsvikt, Kongestiv | Mitokondriell förändring | Hjärtsvikt New York Heart Association Klass IVFörenta staterna
-
Novartis PharmaceuticalsAvslutadPatienter som framgångsrikt slutfört den 12 månader långa behandlingsperioden i kärnstudien (de Novo Heart Recipients) som var intresserade av att bli behandlad med EC-MPS
-
University Hospital, GasthuisbergOkändTransient Left Ventricular Ballooning SyndromeBelgien
-
Children's Hospital Medical Center, CincinnatiRekryteringNationellt samarbete för att förbättra vården av barn med komplexa medfödda hjärtsjukdomar (NPC-QIC)Hypoplastiskt Left Heart Syndrome (HLHS)Förenta staterna, Storbritannien, Kanada
-
Lifetech Scientific (Shenzhen) Co., Ltd.OkändPatent Ductus Arteriosus | Kanalberoende Cyanotic Congenital Heart DiseaseMalaysia
-
Mayo ClinicRekryteringHypoplastiskt Left Heart Syndrome (HLHS)Förenta staterna
-
NYU Langone HealthRekryteringTako-tsubo kardiomyopati | Takotsubo kardiomyopati | Broken Heart SyndromeFörenta staterna
Kliniska prövningar på Enhanced External Counterpulsa
-
Chi-Ming ChuDr. Chiang, Shang-lin; Dr. Liang-Cheng ChenRekryteringHjärteffekt | Enhanced External Counterpulsation (EECP) | HjärtkraftsindexTaiwan
-
David Grant U.S. Air Force Medical CenterIndragenKardiovaskulär sjukdom | LungsjukdomFörenta staterna
-
David Grant U.S. Air Force Medical CenterAvslutad
-
Guohua ZengOkänd
-
Baxter Healthcare CorporationDuke UniversityRekrytering
-
Sun Yat-sen UniversityAvslutadÅderförkalkningKina
-
Saluda Medical Pty LtdAvslutad
-
McMaster UniversityUniversity of British Columbia; Canadian Institutes of Health Research...Avslutad
-
University of DelawareRekryteringAlzheimers sjukdom | Lätt kognitiv funktionsnedsättningFörenta staterna
-
Cardialen, Inc.Iqvia Pty LtdAvslutadFörmaksflimmer | Paroxysmalt förmaksflimmer | Ihållande förmaksflimmerFörenta staterna